Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04468958 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants
A Phase 1 study, sponsored by SAb Biotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT04468958 is a Phase 1 study that has completed, run by SAb Biotherapeutics. The registered enrollment target is 28 participants.
The verdict
NCT04468958, a Phase 1 study, has completed, sponsored by SAb Biotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SAB Biotherapeutics has developed SAB-185, an Anti-SARS-CoV-2 Human Immunoglobulin Intravenous (transchromosomic \[Tc\] bovine-derived), as a potential therapeutic to treat COVID-19. This study will evaluate the safety, immunogenicity, and pharmacokinetics of SAB-185 in healthy participants.
Interventions
- OTHER Normal saline
- BIOLOGICAL SAB-185
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2020-07-01 |
| Est. Completion | 2020-12-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04468958
The ClinicalTrials.gov registry entry for NCT04468958 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SAb Biotherapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Normal saline is the first listed.
NCT04468958 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04468958 about?
NCT04468958 is a clinical study titled "Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants". Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SAB Biotherapeutics has developed SAB-185, an Anti-SARS-CoV-2 Human Immunoglobulin Intravenous (transchromosomic \[Tc\] bovine-derived), as a potential therapeutic to ...
What is the current status of trial NCT04468958?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2020-07-01. Estimated completion is 2020-12-23.
What interventions are being tested in trial NCT04468958?
The interventions under investigation include: Normal saline (OTHER), SAB-185 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04468958?
This trial is sponsored by SAb Biotherapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.